Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

Johannes M. Waldschmidt, Alexander Keller, Gabriele Ihorst, Olga Grishina, Stefan Müller, Dagmar Wider, Anna V. Frey, Kristina King, Roman Simon, Annette May, Pierfrancesco Tassone, Justus Duyster, Manfred Jung, Noopur Raje, Ralph Wäsch, and Monika Engelhardt

Disclosures: M. Engelhardt (ME) has received an IIT restricted study grant from Janssen and MSD and ME and R. Wäsch (RW) a Faculty grant from the Forschungskommission UKF to support the VBDD trial. The functional assessment was supported by the Deutsche Krebshilfe [DKH 1095969+111424, ME and RW]. The HDAC activity changes in PBMCs were supported by the Deutsche Forschungsgemeinschaft (DFG, Ju 295/13-1).

Contributions: The study was designed by the investigators in collaboration with the sponsors. Data were obtained by the investigators and staff at Clinical Trials Center Freiburg; all authors had access to the study data. The manuscript was written by ME. All authors met the criteria for authorship set forth by the international Committee for Medical Journal Editors.